vadimezan has been researched along with thromboxane a2 in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, G; Ding, Z; Gu, J; Kunapuli, SP; Mruk, JS; Shen, J; Zhang, S; Zhang, SH; Zhang, Y; Zhu, L | 1 |
1 other study(ies) available for vadimezan and thromboxane a2
| Article | Year |
|---|---|
Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Triphosphate; Animals; Antineoplastic Agents; Humans; MAP Kinase Signaling System; Mice; Phosphodiesterase Inhibitors; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Thrombosis; Thromboxane A2; Thromboxane-A Synthase; Xanthones | 2013 |